Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 28, 2013; 19(24): 3854-3860
Published online Jun 28, 2013. doi: 10.3748/wjg.v19.i24.3854
Published online Jun 28, 2013. doi: 10.3748/wjg.v19.i24.3854
Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma
Zhong Wu, Xin Wang, Yong-Bin Li, Bing Peng, Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jin Zhou, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Ting Niu, Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Wu Z and Zhou J contributed equally to this work; Wu Z and Zhou J made substantial contributions to the conception and design of the study, data acquisition, and data analysis and interpretation; Wu Z, Wang X and Li YB drafted the article and revised it critically for important intellectual content; Peng B and Niu T provided final approval of the version to be published.
Correspondence to: Bing Peng, MD, Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, Sichuan Province, China. pengbing84@hotmail.com
Telephone: +86-28-85422474 Fax: +86-28-85422474
Received: January 10, 2013
Revised: April 28, 2013
Accepted: May 17, 2013
Published online: June 28, 2013
Revised: April 28, 2013
Accepted: May 17, 2013
Published online: June 28, 2013
Core Tip
Core tip: Laparoscopic splenectomy (LS) achieves excellent results for treatment of benign hematological diseases. The role of LS in treatment of splenic marginal zone lymphoma (SMZL) is difficult to define due to the associated splenomegaly, which may influence long-term outcomes. We investigated the perioperative variables and long-term follow-up of 18 SMZL patients who underwent LS and compared them with SMZL patients who underwent open splenectomy, immune thrombocytopenia patients who underwent LS, and liver cirrhosis patients who underwent LS. LS should be considered an appropriate treatment strategy for SMZL patients in an effort to improve the treatment options and survival of these patients.